Notice for International Patients & Caregivers

English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.

Provincial Landscape

Snapshot: 2026-09-04

Anhui Multiple Myeloma Active Trials & Centers

As of 2026-09-04, there are 21 active clinical trials for multiple myeloma hosted across 16 tertiary medical centers in Anhui (including The Second Affiliated Hospital of Anhui Medical University, Yijishan Hospital of Wannan Medical College (The First Affiliated Hospital of Wannan Medical College), Anhui Provincial Cancer Hospital, etc.).

Active Trials

Hospitals

Therapies

CAR-T Cell Therapy / Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents

Participating Medical Centers (16)

The Second Affiliated Hospital of Anhui Medical UniversityYijishan Hospital of Wannan Medical College (The First Affiliated Hospital of Wannan Medical College)Anhui Provincial Cancer HospitalAnhui Provincial HospitalThe First Affiliated Hospital of Anhui Medical UniversityAnhui Second People's HospitalBozhou People's HospitalThe First Affiliated Hospital of Wannan Medical CollegeHuangshan People's HospitalThe First Affiliated Hospital of USTC (Anhui Provincial Hospital)The First Affiliated Hospital of USTCThe First Affiliated Hospital of USTC (Anhui Provincial Hospital)The First Affiliated Hospital of Bengbu Medical UniversityThe First Affiliated Hospital of Bengbu Medical CollegeLu'an People's HospitalFuyang Hospital of Anhui Medical University

Active Studies in Anhui (21)

Population synthesized by CMDN

Showing 0 published English records of 21 registry trials.

All 21 local registry studies currently have Chinese-only filings. Verified English summaries will be published upon regulatory audit.

Back to National Landscape Filter Local Trials in the Trial Hub